Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.22 | -5.86666666667 | 3.75 | 3.75 | 3.23 | 433451 | 3.4449574 | CS |
4 | -0.42 | -10.6329113924 | 3.95 | 4.27 | 3.23 | 606760 | 3.85205976 | CS |
12 | -4.47 | -55.875 | 8 | 9.5 | 3.01 | 825457 | 5.82230853 | CS |
26 | -6.76 | -65.6948493683 | 10.29 | 10.37 | 3.01 | 674184 | 6.54552935 | CS |
52 | -0.58 | -14.1119221411 | 4.11 | 13.68 | 3.01 | 622496 | 7.65483703 | CS |
156 | -5.48 | -60.8213096559 | 9.01 | 13.68 | 1.53 | 335056 | 6.21442405 | CS |
260 | -8.47 | -70.5833333333 | 12 | 25.87 | 1.53 | 243461 | 6.95454113 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관